These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1117 related articles for article (PubMed ID: 24440671)

  • 1. Interactions between the intestinal microbiome and liver diseases.
    Schnabl B; Brenner DA
    Gastroenterology; 2014 May; 146(6):1513-24. PubMed ID: 24440671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
    Chen P; Torralba M; Tan J; Embree M; Zengler K; Stärkel P; van Pijkeren JP; DePew J; Loomba R; Ho SB; Bajaj JS; Mutlu EA; Keshavarzian A; Tsukamoto H; Nelson KE; Fouts DE; Schnabl B
    Gastroenterology; 2015 Jan; 148(1):203-214.e16. PubMed ID: 25239591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gut microbiota in liver disease.
    Albhaisi SAM; Bajaj JS; Sanyal AJ
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G84-G98. PubMed ID: 31657225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking intestinal homeostasis and liver disease.
    Schnabl B
    Curr Opin Gastroenterol; 2013 May; 29(3):264-70. PubMed ID: 23493073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-microbiome interactions in alcoholic liver disease.
    Chen P; Schnabl B
    Gut Liver; 2014 May; 8(3):237-41. PubMed ID: 24827618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric dysbiosis associated with a mouse model of alcoholic liver disease.
    Yan AW; Fouts DE; Brandl J; Stärkel P; Torralba M; Schott E; Tsukamoto H; Nelson KE; Brenner DA; Schnabl B
    Hepatology; 2011 Jan; 53(1):96-105. PubMed ID: 21254165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
    Wieland A; Frank DN; Harnke B; Bambha K
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.